275 related articles for article (PubMed ID: 24793883)
1. Synthesis and optimization of an original V-shaped collection of 4-7-disubstituted pyrido[3,2-d]pyrimidines as CDK5 and DYRK1A inhibitors.
Dehbi O; Tikad A; Bourg S; Bonnet P; Lozach O; Meijer L; Aadil M; Akssira M; Guillaumet G; Routier S
Eur J Med Chem; 2014 Jun; 80():352-63. PubMed ID: 24793883
[TBL] [Abstract][Full Text] [Related]
2. Kinase inhibitions in pyrido[4,3-h] and [3,4-g]quinazolines: Synthesis, SAR and molecular modeling studies.
Zeinyeh W; Esvan YJ; Josselin B; Baratte B; Bach S; Nauton L; Théry V; Ruchaud S; Anizon F; Giraud F; Moreau P
Bioorg Med Chem; 2019 May; 27(10):2083-2089. PubMed ID: 30967303
[TBL] [Abstract][Full Text] [Related]
3. New pyrido[3,4-g]quinazoline derivatives as CLK1 and DYRK1A inhibitors: synthesis, biological evaluation and binding mode analysis.
Tazarki H; Zeinyeh W; Esvan YJ; Knapp S; Chatterjee D; Schröder M; Joerger AC; Khiari J; Josselin B; Baratte B; Bach S; Ruchaud S; Anizon F; Giraud F; Moreau P
Eur J Med Chem; 2019 Mar; 166():304-317. PubMed ID: 30731399
[TBL] [Abstract][Full Text] [Related]
4. Synthesis of new pyridazino[4,5-b]indol-4-ones and pyridazin-3(2H)-one analogs as DYRK1A inhibitors.
Bruel A; Bénéteau R; Chabanne M; Lozach O; Le Guevel R; Ravache M; Bénédetti H; Meijer L; Logé C; Robert JM
Bioorg Med Chem Lett; 2014 Nov; 24(21):5037-40. PubMed ID: 25248682
[TBL] [Abstract][Full Text] [Related]
5. Synthesis and molecular modelling studies of 8-arylpyrido[3',2':4,5]thieno[3,2-d]pyrimidin-4-amines as multitarget Ser/Thr kinases inhibitors.
Loidreau Y; Deau E; Marchand P; Nourrisson MR; Logé C; Coadou G; Loaëc N; Meijer L; Besson T
Eur J Med Chem; 2015 Mar; 92():124-34. PubMed ID: 25549552
[TBL] [Abstract][Full Text] [Related]
6. Synthesis, biological evaluation and molecular modeling studies of imidazo[1,2-a]pyridines derivatives as protein kinase inhibitors.
Lawson M; Rodrigo J; Baratte B; Robert T; Delehouzé C; Lozach O; Ruchaud S; Bach S; Brion JD; Alami M; Hamze A
Eur J Med Chem; 2016 Nov; 123():105-114. PubMed ID: 27474927
[TBL] [Abstract][Full Text] [Related]
7. Meridianin derivatives as potent Dyrk1A inhibitors and neuroprotective agents.
Yadav RR; Sharma S; Joshi P; Wani A; Vishwakarma RA; Kumar A; Bharate SB
Bioorg Med Chem Lett; 2015 Aug; 25(15):2948-52. PubMed ID: 26048785
[TBL] [Abstract][Full Text] [Related]
8. Pyrido[2,3-d]pyrimidines: discovery and preliminary SAR of a novel series of DYRK1B and DYRK1A inhibitors.
Anderson K; Chen Y; Chen Z; Dominique R; Glenn K; He Y; Janson C; Luk KC; Lukacs C; Polonskaia A; Qiao Q; Railkar A; Rossman P; Sun H; Xiang Q; Vilenchik M; Wovkulich P; Zhang X
Bioorg Med Chem Lett; 2013 Dec; 23(24):6610-5. PubMed ID: 24239188
[TBL] [Abstract][Full Text] [Related]
9. Design, synthesis, and molecular modelling of pyridazinone and phthalazinone derivatives as protein kinases inhibitors.
Elagawany M; Ibrahim MA; Ali Ahmed HE; El-Etrawy ASh; Ghiaty A; Abdel-Samii ZK; El-Feky SA; Bajorath J
Bioorg Med Chem Lett; 2013 Apr; 23(7):2007-13. PubMed ID: 23453843
[TBL] [Abstract][Full Text] [Related]
10. Insights into mechanism of pyrido[2,3-d]pyrimidines as DYRK1A inhibitors based on molecular dynamic simulations.
Li JJ; Tian YL; Zhai HL; Lv M; Zhang XY
Proteins; 2016 Aug; 84(8):1108-23. PubMed ID: 27119584
[TBL] [Abstract][Full Text] [Related]
11. Synthesis and biological evaluation of 3,6-diamino-1H-pyrazolo[3,4-b]pyridine derivatives as protein kinase inhibitors.
Chioua M; Samadi A; Soriano E; Lozach O; Meijer L; Marco-Contelles J
Bioorg Med Chem Lett; 2009 Aug; 19(16):4566-9. PubMed ID: 19615897
[TBL] [Abstract][Full Text] [Related]
12. Potent inhibitors of CDK5 derived from roscovitine: synthesis, biological evaluation and molecular modelling.
Demange L; Abdellah FN; Lozach O; Ferandin Y; Gresh N; Meijer L; Galons H
Bioorg Med Chem Lett; 2013 Jan; 23(1):125-31. PubMed ID: 23218601
[TBL] [Abstract][Full Text] [Related]
13. Synthesis of novel 7-substituted pyrido[2',3':4,5]furo[3,2-d]pyrimidin-4-amines and their N-aryl analogues and evaluation of their inhibitory activity against Ser/Thr kinases.
Deau E; Loidreau Y; Marchand P; Nourrisson MR; Loaëc N; Meijer L; Levacher V; Besson T
Bioorg Med Chem Lett; 2013 Dec; 23(24):6784-8. PubMed ID: 24176400
[TBL] [Abstract][Full Text] [Related]
14. Design, Synthesis and Bioactivity Evaluation of 4,6-Disubstituted Pyrido[3,2-
Xing K; Zhang J; Han Y; Tong T; Liu D; Zhao L
Molecules; 2020 Sep; 25(18):. PubMed ID: 32967084
[TBL] [Abstract][Full Text] [Related]
15. Multi-step virtual screening to develop selective DYRK1A inhibitors.
Koyama T; Yamaotsu N; Nakagome I; Ozawa SI; Yoshida T; Hayakawa D; Hirono S
J Mol Graph Model; 2017 Mar; 72():229-239. PubMed ID: 28129593
[TBL] [Abstract][Full Text] [Related]
16. 10-iodo-11H-indolo[3,2-c]quinoline-6-carboxylic acids are selective inhibitors of DYRK1A.
Falke H; Chaikuad A; Becker A; Loaëc N; Lozach O; Abu Jhaisha S; Becker W; Jones PG; Preu L; Baumann K; Knapp S; Meijer L; Kunick C
J Med Chem; 2015 Apr; 58(7):3131-43. PubMed ID: 25730262
[TBL] [Abstract][Full Text] [Related]
17. Structure-Guided Discovery of Potent and Selective DYRK1A Inhibitors.
Weber C; Sipos M; Paczal A; Balint B; Kun V; Foloppe N; Dokurno P; Massey AJ; Walmsley DL; Hubbard RE; Murray J; Benwell K; Edmonds T; Demarles D; Bruno A; Burbridge M; Cruzalegui F; Kotschy A
J Med Chem; 2021 May; 64(10):6745-6764. PubMed ID: 33975430
[TBL] [Abstract][Full Text] [Related]
18. Synthesis and kinase inhibitory activity of novel substituted indigoids.
Beauchard A; Laborie H; Rouillard H; Lozach O; Ferandin Y; Le Guével R; Guguen-Guillouzo C; Meijer L; Besson T; Thiéry V
Bioorg Med Chem; 2009 Sep; 17(17):6257-63. PubMed ID: 19665384
[TBL] [Abstract][Full Text] [Related]
19. Discovery of pyrido[3,4-g]quinazoline derivatives as CMGC family protein kinase inhibitors: Design, synthesis, inhibitory potency and X-ray co-crystal structure.
Esvan YJ; Zeinyeh W; Boibessot T; Nauton L; Théry V; Knapp S; Chaikuad A; Loaëc N; Meijer L; Anizon F; Giraud F; Moreau P
Eur J Med Chem; 2016 Aug; 118():170-7. PubMed ID: 27128181
[TBL] [Abstract][Full Text] [Related]
20. Advances in tetrahydropyrido[1,2-a]isoindolone (valmerins) series: Potent glycogen synthase kinase 3 and cyclin dependent kinase 5 inhibitors.
Boulahjar R; Ouach A; Bourg S; Bonnet P; Lozach O; Meijer L; Guguen-Guillouzo C; Le Guevel R; Lazar S; Akssira M; Troin Y; Guillaumet G; Routier S
Eur J Med Chem; 2015 Aug; 101():274-87. PubMed ID: 26142492
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]